Joint research on antibody drugs for autoimmune diseases with Mitsubishi Tanabe Pharma

「A Phase I clinical trial conducted by Tanabe Pharma Corporation in healthy adult male volunteers to evaluate the safety, tolerability and pharmacokinetics of this antibody drug candidate (clinical trial ID: jRCT2031240187) was completed in July 2025.」

「The company is also advancing various pharmacological efficacy studies on the anti-PAD2 antibody and negotiations for partnerships with major pharmaceutical companies in Japan and overseas.」

「In particular, for the anti-PAD2 antibody, we are advancing various pharmacological efficacy studies and negotiations for partnerships with major domestic and overseas pharmaceutical companies. For various intractable diseases, including malignant tumors, we are conducting pharmacological efficacy studies using anti-FSTL1 antibodies and other agents and advancing negotiations for partnerships with major pharmaceutical companies.」

「Based on these results, we and Mitsubishi Tanabe Pharma Corporation entered into an exclusive licensing agreement in January 2021. Going forward, we will receive development milestone payments according to the stage of development. If this antibody drug is launched into the ¥5 trillion antibody drug market for autoimmune diseases, we will also receive royalties based on worldwide sales and sales milestone payments.」

「Under the Autoimmune Disease Project, the company had pursued joint research with Mitsubishi Tanabe Pharma Corporation on antibody drugs for two years from October 2018. Based on the results, the company and Mitsubishi Tanabe Pharma Corporation decided to enter into an exclusive license agreement and advance the program to the development stage as an antibody drug. Upon execution of the agreement, the company recorded ¥320 million as an upfront payment.」

「As a result, the company achieved the joint research objectives and made steady progress toward an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation. If the agreement is executed, the company is expected to substantially change its earnings structure by receiving an upfront payment, milestone income at each development stage and royalties based on drug sales.」

「Good results have been obtained in the evaluation studies, and steady progress has been made toward a licensing agreement during the current fiscal year, increasing the likelihood that this will become a long-term source of revenue.」

「Good results have been obtained in the evaluation studies, and steady progress has been made toward a licensing agreement during the current fiscal year, increasing the likelihood that this will become a source of revenue.」

「Under the Autoimmune Disease Project, the company is conducting joint research with Mitsubishi Tanabe Pharma Corporation on antibody drugs targeting the treatment of autoimmune diseases, and the program is progressing steadily with the aim of advancing to the development stage at an early date.」

「Under the Autoimmune Disease Project, the company is conducting joint research with Mitsubishi Tanabe Pharma Corporation on antibody drugs targeting the treatment of autoimmune diseases, with the aim of advancing the program to the development stage at an early date.」

「During the consolidated first-quarter cumulative period, in the Biomedical Business, the company entered into a joint research agreement with Mitsubishi Tanabe Pharma Corporation on antibody drugs targeting the treatment of autoimmune diseases. Under the agreement, the two companies will use their respective technologies to improve antibodies against drug discovery target molecules for autoimmune diseases identified by the company, with the aim of creating new antibody drugs. Under the joint research agreement, the company will receive up to ¥250 million from Mitsubishi Tanabe Pharma Corporation as an upfront payment and research milestones.」